Zai Lab Limited
As of Oct 22, 2026, Zai Lab is in Stage 2, the uptrend phase, now in week 10 (since Aug 17, 2026). It closed at $22.04, 24.2% below its 52-week high and above its 200-day average, which is rising.
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is ZLAB early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
ZLAB among Biotechnology260th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …260 | ZLAB | Stage 2 · wk 10 | 37 | −16.6% |
Zai Lab: quick answers
What stage is Zai Lab in?
As of Oct 22, 2026, Zai Lab (ZLAB) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 17, 2026 and is in week 10. What the four stages mean
Is Zai Lab in an uptrend?
Yes. Zai Lab is in a Stage 2 uptrend. It trades 5.7% above its 200-day average, which is rising.
How far is Zai Lab from its 52-week high?
Zai Lab closed at $22.04 on Oct 22, 2026, 24.2% below its 52-week high of $29.09. Its 52-week low is $16.30.
How has Zai Lab performed over the past year?
As of Oct 22, 2026, Zai Lab is down 24.4% over the past year and up 27.2% so far in 2026.
Which sector and industry is Zai Lab in?
Zai Lab is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.